221 related articles for article (PubMed ID: 28645632)
1. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
Woodard GA; Wang SX; Kratz JR; Zoon-Besselink CT; Chiang CY; Gubens MA; Jahan TM; Blakely CM; Jones KD; Mann MJ; Jablons DM
Clin Lung Cancer; 2018 Jan; 19(1):58-64. PubMed ID: 28645632
[TBL] [Abstract][Full Text] [Related]
2. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
Woodard GA; Gubens MA; Jahan TM; Jones KD; Kukreja J; Theodore PR; Cardozo S; Jew G; Clary-Macy C; Jablons DM; Mann MJ
Clin Lung Cancer; 2014 Nov; 15(6):426-32. PubMed ID: 25258195
[TBL] [Abstract][Full Text] [Related]
3. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
4. [Effect of Adjuvant Chemotherapy on DFS for Patients with Stage I NSCLC].
Peng S; Li X; Wang Y; Liu J
Zhongguo Fei Ai Za Zhi; 2017 Jul; 20(7):485-489. PubMed ID: 28738965
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
[TBL] [Abstract][Full Text] [Related]
6. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
Woodard GA; Kratz JR; Haro G; Gubens MA; Blakely CM; Jones KD; Mann MJ; Jablons DM
Clin Lung Cancer; 2021 Nov; 22(6):587-595. PubMed ID: 34544620
[TBL] [Abstract][Full Text] [Related]
7. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
8. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
[TBL] [Abstract][Full Text] [Related]
9. Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer.
Van Laar RK
BMC Med Genomics; 2012 Jul; 5():30. PubMed ID: 22748043
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer.
Zhai W; Duan F; Li D; Yan Q; Dai S; Zhang B; Wang J
Eur J Surg Oncol; 2022 Apr; 48(4):752-760. PubMed ID: 34620508
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.
Ding H; Gui X; Lin X; Chen R; Ma T; Sheng Y; Cai H; Fen Y
Technol Cancer Res Treat; 2017 Oct; 16(5):645-653. PubMed ID: 27688262
[TBL] [Abstract][Full Text] [Related]
12. Use of adjuvant chemotherapy for nonsmall cell lung cancer: Is advanced age a prognostic factor?
Batum O; Anar C; Özdoğan Y; Ermin S; Yılmaz U
Indian J Cancer; 2018; 55(3):282-287. PubMed ID: 30693895
[TBL] [Abstract][Full Text] [Related]
13. Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States.
Smeltzer MP; Lin CC; Kong FS; Jemal A; Osarogiagbon RU
J Thorac Cardiovasc Surg; 2017 Aug; 154(2):661-672.e10. PubMed ID: 28483267
[TBL] [Abstract][Full Text] [Related]
14. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Zhai X; Yang L; Chen S; Zheng Q; Wang Z
Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
[TBL] [Abstract][Full Text] [Related]
15. The coming of age of molecular tumor profiling.
Antonoff MB; D'Cunha J
Semin Thorac Cardiovasc Surg; 2011; 23(1):8-9. PubMed ID: 21807290
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
17. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
[TBL] [Abstract][Full Text] [Related]
18. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
[TBL] [Abstract][Full Text] [Related]
19. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
Wang K; Li Y; Wang J; Chen R; Li J
Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
[TBL] [Abstract][Full Text] [Related]
20. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
Gupta AR; Woodard GA; Jablons DM; Mann MJ; Kratz JR
Future Oncol; 2021 Dec; 17(34):4785-4795. PubMed ID: 34435876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
